BoironBOIRF 62 FCF Yield % is 6.18 as of Jun. 26, 2026, which is 26% above its 10-year median of 4.91. GuruFocus rates BOIRF with a GF Score™ of 62/100 and a GF Value™ of $33.65 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Boiron ranks better than 77.01% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Boiron's Trailing 12-Month Free Cash Flow is $34.5 Mil, and Market Cap is $551.9 Mil. Therefore, Boiron's FCF Yield % for today is 6.18%.
The historical rank and industry rank for Boiron's FCF Yield % or its related term are showing as below:
BOIRF'
s FCF Yield % Range Over the Past 10 Years
Min: 1.45 Med: 4.91 Max: 7.94
Current: 6.18
During the past 13 years, the highest FCF Yield % of Boiron was 7.94%. The lowest was 1.45%. And the median was 4.91%.
BOIRF's FCF Yield % is ranked better than 77.01% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.67
vs BOIRF: 6.18
Boiron's FCF Margin % for the quarter that ended in Dec. 2025 was 4.08%.
Boiron FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Boiron FCF Yield % Related Terms
Boiron FCF Yield % Historical Data
* Premium members only.
The historical data trend for Boiron's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boiron FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Boiron's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Boiron's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boiron (BOIRF) has a FCF Yield % of 6.18 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Boiron and its competitors. This is 26% above median its historical median of 4.91. Over the past decade, Boiron's FCF Yield % has ranged from 1.45 to 7.94. According to the industry distribution chart, Boiron ranks #231 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 23%.
Is Boiron's FCF Yield % too high?
Boiron's current FCF Yield % of 6.18 is 26% above median its 10-year median of 4.91. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 7.94. The Drug Manufacturers industry median FCF Yield % is 0.67. Boiron's value of 6.18 is 822.4% above this industry median. Based on the distribution chart, Boiron ranks #231 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Boiron has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Boiron's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Boiron ranks #231 out of 1005 companies for FCF Yield %. This places Boiron in the top 23% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. Boiron's value of 6.18 is 822.4% above this benchmark. Historically, Boiron's own FCF Yield % has ranged from 1.45 to 7.94 over the past decade. While the company's 10-year median is 4.91 vs. the industry median of 0.67, Boiron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boiron's current FCF Yield % of 6.18 is 822.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Boiron and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boiron's current FCF Yield % is 6.18, which is 26% above median its own 10-year median of 4.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boiron stock overvalued right now?
Based on GuruFocus' analysis, Boiron (BOIRF) is currently considered Fairly Valued. The stock's GF Value™ is $33.65, compared to a current price of $31.90 — trading 5.2% below its estimated fair value. The current FCF Yield % is 6.18, which is 26% above median its 10-year median of 4.91 and 822.4% above the Drug Manufacturers industry median of 0.67. Boiron's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Boiron (BOIRF), the current FCF Yield % is 6.18 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boiron (BOIRF) Overvalued in 2026?
Based on GuruFocus' analysis, Boiron stock appears to be undervalued.
The current stock price of $31.90 is trading 5.2% below its estimated GF Value™ of $33.65.
GuruFocus considers Boiron to be Fairly Valued.
Key valuation signals for BOIRF:
FCF Yield %: 6.18 (26% above median its 10-year median of 4.91)
GF Value™: $33.65 vs. price of $31.90 (5.2% below fair value)
Industry Position: 822.4% above the Drug Manufacturers median (#231 of 1005)
No single metric tells the full story. See the BOIRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
62GF Score
Get the complete analysis for BOIRF
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOIRF has been successfully added to your 
